Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases. The company's lead program, EXPD-101, is a next-generation once-daily DPP1 inhibitor with first-in-class potential in COPD and first/best-in-class potential across a broad spectrum of other neutrophil-driven diseases. Expedition combines deep translational expertise, clinical development experience, and a platform for in-licensing global innovation.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/09/25	$165,000,000	Series A	Adage Capital Management Balyasny Asset Management BVF Partners Dawn Biopharma Forbion Capital Partners Logos Capital Novo Holdings Sanofi Ventures Sofinnova Investments Venrock Healthcare Partners	undisclosed